Calamos Advisors
BIOSU

Calamos Advisors’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

Calamos Advisors’s Portfolio BIOSU Stock Details BIOSU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000,000
Closed -$10.1M – 1407
2022
Q3 		$10.1M Hold
1,000,000
– – 0.05% 480
2022
Q2 		$10.1M Hold
1,000,000
– – 0.04% 483
2022
Q1 		$9.99M Hold
1,000,000
– – 0.04% 529
2021
Q4 		$10M Buy
+1,000,000
New +$10M 0.04% 494

Other funds holding BIOSU

HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Calamos Advisors's BIOSU Position: Q4 2022 in Review

Calamos Advisors sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q4 2022, closing a stake of 1,000,000 shares — an estimated $10.1M sold.

Calamos Advisors first reported a position in BIOSU in Q4 2021 and held it in 4 quarters. The position peaked at $10.1M in Q2 2022. 11 funds tracked by Wall St. Rank hold BIOSU as of Q4 2022.

  • Calamos Advisors reported no remaining BioPlus Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 1,000,000 BioPlus Acquisition Corp. Unit shares in Q4 2022, an estimated $10.1M.
  • Calamos Advisors first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
  • Calamos Advisors's BioPlus Acquisition Corp. Unit position peaked at $10.1M in Q2 2022.
  • 11 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.